Database Offers Pan-Cancer Landscape of 3’UTR Splicing

Scientists have created an interactive web-based platform for cancer researchers to interrogate how RNA splicing in noncoding parts of genes fuels the growth of different types of tumors. The new resource, named SpUR (SPLicing in Untranslated Regions) and freely available online, details over 1,000 splicing events found frequently in cancers in noncoding regions of mRNA located just downstream of protein-coding stop signals. The sites and expression levels of these events are cataloged and visualized for nearly 8,000 samples across 10 cancer types and corresponding normal tissues.

With the tool, independent research teams can now further probe the role of individual splice events in cancer development and progression. “These events could become candidates to study RNA dysregulations in cancer for academic researchers,” says Xin Gao, acting associate director of the Computational Bioscience Research Center and deputy director of the Smart Health Initiative at King Abdullah University of Science and Technology (KAUST).  “Or they could serve as a primary source for the development of RNA-based anti-cancer drugs.” 

Research has shown that splicing in downstream sequences of a gene (known as 3’ untranslated regions, or 3’ UTRs) is pervasive in cancers, especially in genes linked to tumor aggression. Consequently, patients whose cancers harbor more of these gene-restructuring events tend to have poorer survival outcomes.

As a proof of principle, the researchers designed splice-switching agents known as antisense oligonucleotides (ASOs) that could block this splicing process in 3’ UTRs. When administered to liver cancer cells, these drugs helped repress tumor growth. And since the same kinds of splicing events are “ubiquitously expressed across different cancer types,” Gao notes, this type of therapeutic strategy “could be helpful to develop broad-spectrum anti-cancer drugs.”

One such target, CTNNB1, is a gene that provides instructions for making a protein called beta-catenin. Given its central role in many cancer-signaling pathways, drug companies have long tried to target beta-catenin but have had only limited success. The study from Gao and his collaborators showed that splicing in the 3’ UTR of CTNNB1 is widespread across cancers of the liver, breast, colon, kidney, lung and other organs, and that a spliced variant is the predominant driver of tumor progression. In a mouse model of liver cancer, blocking this splicing resulted in complete tumor regression. An antisense oligonucleotides therapy directed at CTNNB1 splicing could therefore have broad utility in patients, and, as Gao points out, it’s not likely to be the only one.

More details on SpUR and the team’s proof-of-principle tests can be found in a recent issue of Nature Cell Biology.